Endocrine therapy reduces the risk of systemic recurrence and death among women with hormone receptor-positive BC, regardless of age, menopausal status, nodal involvement, tumor size, HER2 status, or use of CT.9 Although endocrine therapies are oral drugs that are easy to use and not costly, the inability of patients to receive this treatment may reflect their lack of follow-up. The gene discussed is ERBB2; the disease is breast cancer.